



Advances in Agressive Prostate Cancer

Guest Editor:

Dr. Mireia Olivan

1. Translational Oncology
Laboratory, Anatomy Unit,
Department of Pathology and
Experimental Therapy, School of
Medicine, Universitat de
Barcelona (UB), Feixa Llarga, s/n,
08907 L'Hospitalet de Llobregat,
Spain
2. Oncobell Program, Bellvitge
Biomedical Research Institute
(IDIBELL), Gran Via de
l'Hospitalet 199, 08908
L'Hospitalet de Llobregat, Spain

Deadline for manuscript
submissions:
closed (31 August 2022)

Message from the Guest Editor

Although the survival of prostate cancer (PCa) patients has improved over the last two decades, PCa remains the most prevalent cancer in men. When the disease is diagnosed confined to the organ, it is curable, however once the tumor disseminates to distant organs such as bone, the prognosis drastically worsens. Generally, patients with advanced stage PCa are treated with androgen deprivation therapy (ADT). Unfortunately, in most cases ADT is only effective temporarily; PCa gradually acquires resistance to androgen deprivation and eventually becomes castration resistant prostate cancer (CRPC), often associated to tumor dissemination. Bone metastasis is a common complication of cancer and occurs in around 70% of patients with metastatic PCa. Bone metastasis represents a scenario difficult to treat due to pain, fracture risk and decreased quality of life; importantly, tumors become generally incurable.

This Special issue aims to expand our knowledge of the molecular bases of the PCa progression, thus opening a range of possible new therapeutic targets and predictive markers of poor prognosis that will lead us to improve the treatment of patients with advanced disease.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Maurizio Battino

Department of
Odontostomatologic and
Specialized Clinical Sciences,
Sez-Biochimica, Faculty of
Medicine, Università Politecnica
delle Marche, Via Ranieri 65,
60100 Ancona, Italy

Message from the Editor-in-Chief

The International Journal of Molecular Sciences (*IJMS*, ISSN 1422-0067) is an open access journal, which was established in 2000. The journal aims to provide a forum for scholarly research on a range of topics, including biochemistry, molecular and cell biology, molecular biophysics, molecular medicine, and all aspects of molecular research in chemistry. *IJMS* publishes both original research and review articles, and regularly publishes special issues to highlight advances at the cutting edge of research. We invite you to read recent articles published in *IJMS* and consider publishing your next paper with us.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, MEDLINE, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Biochemistry and Molecular Biology) / CiteScore - Q1 (Inorganic Chemistry)

Contact Us

*International Journal of Molecular
Sciences* Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/ijms
ijms@mdpi.com
X@IJMS_MDPI